ArticleACS medicinal chemistry lettersPublished
Discovery of Potent 1,3-Cyclobutane-Containing Dual A2A/A2B Receptor Antagonists with Low Projected Human Dose for the Treatment of Cancer
11 of 32 authors shown in byline order.
Regional connection
Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source
- Institution
- Merck & Co.
- County
- Montgomery County
Publication record
- Type
- Article
- Venue
- ACS medicinal chemistry letters
- Published
- Topic
- Disease research
- Subject terms
- Combination therapy; Cancer Treatment; Triazoloquinazoline; A2a/a2b Receptor Antagonists
- PubMed ID
- 42157841
- PubMed Central ID
- PMC13181494
- Open access
- Yes, free to read
- Added to directory
- Source checked